Partial cannabis rescheduling fuels federal policy confusion

The Trump administration moved state-licensed medical cannabis products and FDA-approved cannabis products from Schedule I to Schedule III, a partial rescheduling that doesn’t fully normalize cannabis at the federal level. Experts say this is not a broad reclassification and hinges on future FDA decisions, leaving implementation unclear and raising questions about protections for patients, housing and employment, and equity for minority entrepreneurs. A June 29 DEA hearing on rescheduling adds to the uncertainty amid ongoing debate about alignment with the UN Single Convention and overall public support for full legalization.